Intrinsic value of Balchem - BCPC

Previous Close

$78.31

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$78.31

 
Intrinsic value

$35.24

 
Up/down potential

-55%

 
Rating

str. sell

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of BCPC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.18
  6.00
  5.90
  5.81
  5.73
  5.66
  5.59
  5.53
  5.48
  5.43
  5.39
  5.35
  5.31
  5.28
  5.25
  5.23
  5.21
  5.19
  5.17
  5.15
  5.14
  5.12
  5.11
  5.10
  5.09
  5.08
  5.07
  5.06
  5.06
  5.05
  5.05
Revenue, $m
  553
  586
  621
  657
  694
  734
  775
  818
  862
  909
  958
  1,009
  1,063
  1,119
  1,178
  1,240
  1,304
  1,372
  1,443
  1,517
  1,595
  1,677
  1,762
  1,852
  1,946
  2,045
  2,149
  2,258
  2,372
  2,492
  2,618
Variable operating expenses, $m
 
  485
  511
  538
  567
  596
  627
  659
  693
  728
  765
  760
  800
  842
  886
  933
  981
  1,032
  1,086
  1,141
  1,200
  1,262
  1,326
  1,394
  1,465
  1,539
  1,617
  1,699
  1,785
  1,875
  1,970
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  462
  485
  511
  538
  567
  596
  627
  659
  693
  728
  765
  760
  800
  842
  886
  933
  981
  1,032
  1,086
  1,141
  1,200
  1,262
  1,326
  1,394
  1,465
  1,539
  1,617
  1,699
  1,785
  1,875
  1,970
Operating income, $m
  91
  101
  110
  119
  128
  138
  148
  158
  170
  181
  193
  250
  263
  277
  292
  307
  323
  340
  357
  376
  395
  415
  436
  459
  482
  506
  532
  559
  587
  617
  648
EBITDA, $m
  137
  166
  176
  186
  196
  207
  219
  231
  244
  257
  271
  285
  301
  316
  333
  351
  369
  388
  408
  429
  451
  474
  498
  524
  550
  578
  608
  638
  671
  705
  740
Interest expense (income), $m
  7
  9
  9
  10
  11
  12
  13
  14
  15
  16
  17
  19
  20
  21
  23
  24
  26
  27
  29
  31
  33
  34
  37
  39
  41
  43
  46
  48
  51
  54
  57
Earnings before tax, $m
  83
  93
  100
  108
  117
  126
  135
  144
  154
  165
  176
  231
  243
  256
  269
  283
  297
  312
  328
  345
  362
  381
  400
  420
  441
  463
  486
  511
  536
  563
  591
Tax expense, $m
  27
  25
  27
  29
  32
  34
  36
  39
  42
  45
  47
  62
  66
  69
  73
  76
  80
  84
  89
  93
  98
  103
  108
  113
  119
  125
  131
  138
  145
  152
  160
Net income, $m
  56
  68
  73
  79
  85
  92
  98
  105
  113
  120
  128
  169
  178
  187
  196
  206
  217
  228
  240
  252
  264
  278
  292
  307
  322
  338
  355
  373
  391
  411
  432

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  39
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  949
  964
  1,021
  1,080
  1,142
  1,207
  1,274
  1,345
  1,418
  1,495
  1,576
  1,660
  1,749
  1,841
  1,938
  2,039
  2,145
  2,256
  2,373
  2,495
  2,623
  2,758
  2,898
  3,046
  3,201
  3,364
  3,535
  3,714
  3,901
  4,098
  4,305
Adjusted assets (=assets-cash), $m
  910
  964
  1,021
  1,080
  1,142
  1,207
  1,274
  1,345
  1,418
  1,495
  1,576
  1,660
  1,749
  1,841
  1,938
  2,039
  2,145
  2,256
  2,373
  2,495
  2,623
  2,758
  2,898
  3,046
  3,201
  3,364
  3,535
  3,714
  3,901
  4,098
  4,305
Revenue / Adjusted assets
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
Average production assets, $m
  304
  322
  341
  361
  381
  403
  425
  449
  473
  499
  526
  554
  584
  614
  647
  681
  716
  753
  792
  833
  876
  920
  967
  1,017
  1,069
  1,123
  1,180
  1,240
  1,302
  1,368
  1,437
Working capital, $m
  87
  88
  93
  99
  104
  110
  116
  123
  129
  136
  144
  151
  159
  168
  177
  186
  196
  206
  216
  228
  239
  251
  264
  278
  292
  307
  322
  339
  356
  374
  393
Total debt, $m
  280
  268
  293
  319
  345
  373
  402
  433
  465
  498
  533
  569
  607
  647
  689
  733
  779
  827
  877
  930
  985
  1,043
  1,104
  1,168
  1,235
  1,305
  1,379
  1,456
  1,537
  1,623
  1,712
Total liabilities, $m
  428
  416
  441
  467
  493
  521
  550
  581
  613
  646
  681
  717
  755
  795
  837
  881
  927
  975
  1,025
  1,078
  1,133
  1,191
  1,252
  1,316
  1,383
  1,453
  1,527
  1,604
  1,685
  1,771
  1,860
Total equity, $m
  521
  548
  580
  614
  649
  685
  724
  764
  806
  849
  895
  943
  993
  1,046
  1,101
  1,158
  1,218
  1,282
  1,348
  1,417
  1,490
  1,566
  1,646
  1,730
  1,818
  1,911
  2,008
  2,109
  2,216
  2,328
  2,445
Total liabilities and equity, $m
  949
  964
  1,021
  1,081
  1,142
  1,206
  1,274
  1,345
  1,419
  1,495
  1,576
  1,660
  1,748
  1,841
  1,938
  2,039
  2,145
  2,257
  2,373
  2,495
  2,623
  2,757
  2,898
  3,046
  3,201
  3,364
  3,535
  3,713
  3,901
  4,099
  4,305
Debt-to-equity ratio
  0.537
  0.490
  0.510
  0.520
  0.530
  0.540
  0.560
  0.570
  0.580
  0.590
  0.600
  0.600
  0.610
  0.620
  0.630
  0.630
  0.640
  0.650
  0.650
  0.660
  0.660
  0.670
  0.670
  0.680
  0.680
  0.680
  0.690
  0.690
  0.690
  0.700
  0.700
Adjusted equity ratio
  0.530
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  56
  68
  73
  79
  85
  92
  98
  105
  113
  120
  128
  169
  178
  187
  196
  206
  217
  228
  240
  252
  264
  278
  292
  307
  322
  338
  355
  373
  391
  411
  432
Depreciation, amort., depletion, $m
  46
  65
  66
  67
  68
  70
  71
  73
  74
  76
  78
  36
  37
  39
  41
  44
  46
  48
  51
  53
  56
  59
  62
  65
  68
  72
  76
  79
  83
  88
  92
Funds from operations, $m
  113
  132
  139
  146
  154
  161
  170
  178
  187
  196
  206
  204
  215
  226
  238
  250
  263
  276
  290
  305
  321
  337
  354
  372
  390
  410
  431
  452
  475
  499
  524
Change in working capital, $m
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  15
  16
  16
  17
  18
  19
Cash from operations, $m
  108
  137
  134
  141
  148
  156
  163
  172
  180
  189
  199
  197
  207
  218
  229
  241
  253
  266
  280
  294
  309
  325
  341
  358
  376
  395
  415
  436
  458
  481
  505
Maintenance CAPEX, $m
  0
  -19
  -21
  -22
  -23
  -24
  -26
  -27
  -29
  -30
  -32
  -34
  -36
  -37
  -39
  -41
  -44
  -46
  -48
  -51
  -53
  -56
  -59
  -62
  -65
  -68
  -72
  -76
  -79
  -83
  -88
New CAPEX, $m
  -24
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -52
  -54
  -57
  -60
  -63
  -66
  -69
Cash from investing activities, $m
  -134
  -37
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -56
  -59
  -62
  -65
  -68
  -71
  -75
  -79
  -83
  -87
  -92
  -96
  -101
  -106
  -111
  -117
  -122
  -129
  -136
  -142
  -149
  -157
Free cash flow, $m
  -26
  99
  94
  99
  104
  110
  115
  121
  127
  133
  140
  135
  142
  149
  157
  166
  174
  183
  193
  202
  213
  224
  235
  247
  259
  272
  286
  301
  316
  332
  348
Issuance/(repayment) of debt, $m
  -17
  23
  25
  26
  27
  28
  29
  30
  32
  33
  35
  36
  38
  40
  42
  44
  46
  48
  50
  53
  55
  58
  61
  64
  67
  70
  74
  77
  81
  85
  89
Issuance/(repurchase) of shares, $m
  6
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -8
  23
  25
  26
  27
  28
  29
  30
  32
  33
  35
  36
  38
  40
  42
  44
  46
  48
  50
  53
  55
  58
  61
  64
  67
  70
  74
  77
  81
  85
  89
Total cash flow (excl. dividends), $m
  -35
  122
  119
  125
  131
  137
  144
  151
  159
  167
  175
  171
  180
  189
  199
  209
  220
  231
  243
  255
  268
  282
  296
  311
  326
  343
  360
  378
  397
  417
  437
Retained Cash Flow (-), $m
  -57
  -31
  -32
  -34
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -48
  -50
  -52
  -55
  -58
  -60
  -63
  -66
  -69
  -73
  -76
  -80
  -84
  -88
  -92
  -97
  -102
  -107
  -112
  -117
Prev. year cash balance distribution, $m
 
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  96
  87
  91
  96
  101
  106
  111
  117
  123
  129
  123
  130
  137
  144
  152
  160
  168
  177
  186
  195
  205
  216
  227
  238
  250
  263
  276
  290
  305
  320
Discount rate, %
 
  5.20
  5.46
  5.73
  6.02
  6.32
  6.64
  6.97
  7.32
  7.68
  8.07
  8.47
  8.89
  9.34
  9.81
  10.30
  10.81
  11.35
  11.92
  12.51
  13.14
  13.80
  14.49
  15.21
  15.97
  16.77
  17.61
  18.49
  19.41
  20.38
  21.40
PV of cash for distribution, $m
 
  91
  78
  77
  76
  74
  72
  69
  66
  63
  59
  50
  47
  43
  39
  35
  31
  27
  23
  20
  17
  14
  11
  9
  7
  5
  4
  3
  2
  1
  1
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, and medical sterilization industries in the United States and internationally. The company’s SensoryEffects segment offers creamer systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, chocolate systems, ice cream bases and variegates, cereals, grain based snacks, and cereal based ingredients; and microencapsulation solutions for various applications, including food, pharmaceutical, and nutritional ingredients. It also provides human grade choline nutrient products for use in wellness applications. Its Animal Nutrition & Health segment offers microencapsulated products that enhance health and milk production in ruminant animals; chelation technology, which provides enhanced nutrient absorption for species; and choline chloride, an essential nutrient for monogastric animal health. The company’s Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. It also sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage; to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and to customers seeking smaller quantities and whose requirements include utilization in various chemical synthesis applications. Its Industrial Products segment provides derivatives of choline chloride for use in industrial applications; and methylamines, which acts as a building block for the manufacture of choline products, as well as used in industrial applications. The company sells its products through its sales force, independent distributors, and sales agents. Balchem Corporation was founded in 1967 and is headquartered in New Hampton, New York.

FINANCIAL RATIOS  of  Balchem (BCPC)

Valuation Ratios
P/E Ratio 44.4
Price to Sales 4.5
Price to Book 4.8
Price to Tangible Book
Price to Cash Flow 23
Price to Free Cash Flow 29.6
Growth Rates
Sales Growth Rate 0.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -42.9%
Cap. Spend. - 3 Yr. Gr. Rate 24.6%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity 47%
Total Debt to Equity 53.7%
Interest Coverage 13
Management Effectiveness
Return On Assets 6.6%
Ret/ On Assets - 3 Yr. Avg. 7.7%
Return On Total Capital 7.2%
Ret/ On T. Cap. - 3 Yr. Avg. 8.4%
Return On Equity 11.4%
Return On Equity - 3 Yr. Avg. 13.4%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 32.7%
Gross Margin - 3 Yr. Avg. 29.9%
EBITDA Margin 24.6%
EBITDA Margin - 3 Yr. Avg. 23.2%
Operating Margin 16.5%
Oper. Margin - 3 Yr. Avg. 16.2%
Pre-Tax Margin 15%
Pre-Tax Margin - 3 Yr. Avg. 15%
Net Profit Margin 10.1%
Net Profit Margin - 3 Yr. Avg. 10.3%
Effective Tax Rate 32.5%
Eff/ Tax Rate - 3 Yr. Avg. 31.6%
Payout Ratio 19.6%

BCPC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BCPC stock intrinsic value calculation we used $553 million for the last fiscal year's total revenue generated by Balchem. The default revenue input number comes from 2016 income statement of Balchem. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BCPC stock valuation model: a) initial revenue growth rate of 6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.2%, whose default value for BCPC is calculated based on our internal credit rating of Balchem, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Balchem.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BCPC stock the variable cost ratio is equal to 83.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BCPC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Balchem.

Corporate tax rate of 27% is the nominal tax rate for Balchem. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BCPC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BCPC are equal to 54.9%.

Life of production assets of 15.6 years is the average useful life of capital assets used in Balchem operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BCPC is equal to 15%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $521 million for Balchem - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 31.667 million for Balchem is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Balchem at the current share price and the inputted number of shares is $2.5 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
SXT Sensient Techn 81.54 26.80  str.sell
IPHS Innophos Holdi 45.91 20.50  str.sell
MMM 3M 191.50 131.01  sell
ACET Aceto 15.27 19.59  buy
EMN Eastman Chemic 79.31 62.09  sell
BUFF Blue Buffalo P 24.09 32.42  buy

COMPANY NEWS

▶ ETFs with exposure to Balchem Corp. : April 19, 2017   [Apr-19-17 02:12PM  Capital Cube]
▶ Health Products Drive Balchem Corporation's Growth   [Mar-01-17 03:43PM  Motley Fool]
▶ Blachem posts 4Q profit   [08:23AM  Associated Press]
▶ 3 Stocks That Turned $10,000 Into at Least $3.68 Million   [Feb-13-17 12:03PM  Motley Fool]
▶ [$$] LBO Focus: Private Equity Whets Appetite for Ingredients Deals   [Feb-01-17 09:24AM  at The Wall Street Journal]
▶ Balchem Corporation Announces Dividend   [11:29AM  GlobeNewswire]
▶ Is Finisar Corporation (FNSR) A Good Stock To Buy?   [Nov-30-16 03:40PM  at Insider Monkey]
▶ Do Hedge Funds Love KBR, Inc. (KBR)?   [Nov-28-16 08:38AM  at Insider Monkey]
▶ Balchem Corporation Sees Steady Health and Nutrition Growth   [Nov-08-16 11:06AM  at Motley Fool]
▶ ETFs with exposure to Balchem Corp. : May 3, 2016   [May-03-16 01:39PM  at Capital Cube]
▶ Why Balchem Corp.'s Shares Plunged 10.7% Today   [Mar-08-16 03:54PM  at Motley Fool]
▶ Why Balchem Corporation's Shares Popped 14% Today   [Feb-02-16 11:43AM  at Motley Fool]
▶ [$$] No. 1 Stock Over 30 Years? You Will Never Guess   [Jan-30-16 12:29AM  at The Wall Street Journal]
▶ [$$] No. 1 Over 30 Years? You Will Never Guess   [Jan-29-16 07:10PM  at The Wall Street Journal]
▶ The Best Stock Over the Last 30 Years? You've Never Heard of It   [01:24PM  at The Wall Street Journal]
▶ Balchem Corporation Announces Dividend   [08:39AM  GlobeNewswire]
Stock chart of BCPC Financial statements of BCPC
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.